Pharmaceutical cocrystals: along the path to improved medicines.
about
Supramolecular organic frameworks: engineering periodicity in water through host-guest chemistry.Acemetacin cocrystal structures by powder X-ray diffraction.The 1:1 co-crystal of 2-bromo-naphthalene-1,4-dione and 1,8-di-hydroxy-anthracene-9,10-dione: crystal structure and Hirshfeld surface analysis.A 2:1 co-crystal of 2-methyl-benzoic acid and N,N'-bis-(pyridin-4-ylmeth-yl)ethanedi-amide: crystal structure and Hirshfeld surface analysisPharmaceutical cocrystals: walking the talk.Engineering and manufacturing of pharmaceutical co-crystals: a review of solvent-free manufacturing technologies.Towards medicinal mechanochemistry: evolution of milling from pharmaceutical solid form screening to the synthesis of active pharmaceutical ingredients (APIs).The Need for Restructuring the Disordered Science of Amorphous Drug Formulations.Making crystals with a purpose; a journey in crystal engineering at the University of Bologna.Exploring the salt-cocrystal continuum with solid-state NMR using natural-abundance samples: implications for crystal engineering.Atom interaction propensities of oxygenated chemical functions in crystal packings.Hydrogen bonding in the crystal structure of the molecular salt of pyrazole-pyrazolium picrate.Directed self-assembly of fluorescence responsive nanoparticles and their use for real-time surface and cellular imaging.Improving Dissolution Rate of Carbamazepine-Glutaric Acid Cocrystal Through Solubilization by Excess Coformer.Quantification of cation-anion interactions in crystalline monopotassium and monosodium glutamate salts.Alloying barbituric and thiobarbituric acids: from solid solutions to a highly stable keto co-crystal form.Multicomponent crystals of gliclazide and tromethamine: preparation, physico-chemical, and pharmaceutical characterization.Taming photo-induced oxidation degradation of dihydropyridine drugs through cocrystallization.Crystal engineering of a zwitterionic drug to neutral cocrystals: a general solution for floxacins.Synthesis, characterization, and stability study of desloratadine multicomponent crystal formation.Survey and analysis of crystal polymorphism in organic structures.Machine learning for the structure-energy-property landscapes of molecular crystals.Structural studies of crystalline forms of triamterene with carboxylic acid, GRAS and API molecules.Cocrystal of Ibuprofen⁻Nicotinamide: Solid-State Characterization and In Vivo Analgesic Activity Evaluation.Role of Biorelevant Dissolution Media in the Selection of Optimal Salt Forms of Oral Drugs: Maximizing the Gastrointestinal Solubility and in Vitro Activity of the Antimicrobial Molecule, Clofazimine.A Review about Regulatory Status and Recent Patents of Pharmaceutical Co-CrystalsThe effect of the ball to reactant ratio on mechanochemical reaction times studied by in situ PXRDRecent advances in improving oral drug bioavailability by cocrystalsSystematic synthesis of a 6-component organic-salt alloy of naftopidil, and pentanary, quaternary and ternary multicomponent crystals
P2860
Q31081020-94599929-F1B5-4477-A7DF-15577B46DA0DQ33630701-B0CBF471-6417-40FC-9415-47175F737A9CQ33640807-FA441C70-86DF-4C9F-868F-2C17A2EF13D4Q36653204-08EC312C-2E18-4BD7-8DA6-151ACB4C0965Q38856202-EC4E0FE3-597F-4A08-9DF1-E45CD9EDD1C2Q38865422-9177EE44-A058-435E-AF1C-CB6DF4F243AEQ38866596-0C11FC1B-2CF3-41B5-9169-384A4136284CQ39317255-66A27D50-E2E8-42B4-87B9-6B4B457B84ADQ41522278-A0A0B2F7-014E-4C64-B96D-C0F830B34C90Q41522354-0E311668-978C-41AD-8445-8FB6257F9F8BQ42319285-1CFB770F-EA58-48DF-8169-62C76D18552EQ42710929-CD48292A-96CE-49C8-BEA4-331CDF4A08B4Q47141506-BDF5D545-9310-4553-B7BC-A0D7E5EFB874Q47210498-F8FB4759-CA8C-4513-9103-9B7E77DC8D34Q47434725-CB747A43-681F-4513-967C-6833DE18BF00Q48313049-2C6DB3AF-D77E-480A-906E-00D8199D58D0Q49687596-D9C0BCDE-0D92-4190-A696-9F6F98F1DE4CQ50067107-2EE1EBCB-710F-4501-A4ED-FC113EEB7814Q51135600-679E8EBB-1FA8-4BBA-A486-9B6CBFB8F76EQ52614621-D3EBA73E-993D-4DFB-90EC-11816133E1A7Q54943838-F921B573-D6FB-480C-84AB-4BE7D430E885Q55280873-C2941694-8CF8-4AED-8885-B2DC2E7B9C22Q55394847-E6D8F260-116F-415D-9E6C-3244598A8757Q55424195-352E4E8F-4733-4E08-BB6B-DF7D9319B523Q55664963-ED5173A0-1338-4D90-9BD2-1F689A1B1A9AQ57136283-AC676ACD-EC4A-4904-9D61-2E100A9C9FEBQ57599062-5E49792F-BF70-42E9-B252-BD048013B342Q58578289-EA24B910-0C83-4A37-9D2A-D14AC041B917Q59133321-9945C798-2F86-4247-A6A8-35071F357A9D
P2860
Pharmaceutical cocrystals: along the path to improved medicines.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Pharmaceutical cocrystals: along the path to improved medicines.
@en
type
label
Pharmaceutical cocrystals: along the path to improved medicines.
@en
prefLabel
Pharmaceutical cocrystals: along the path to improved medicines.
@en
P2093
P2860
P356
P1476
Pharmaceutical cocrystals: along the path to improved medicines.
@en
P2093
Miranda L Perry
Naga K Duggirala
Örn Almarsson
P2860
P304
P356
10.1039/C5CC08216A
P407
P577
2015-11-13T00:00:00Z